France: CJEU issues decision on reconditioning by parallel importers

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

France: CJEU issues decision on reconditioning by parallel importers

Sponsored by

beau-de-lomenie.png

Jurisprudence has had fixed rules for a long time on the reconditioning of pharmaceutical products by parallel importers, without the consent of the trade mark owner.

The reconditioning must not affect the original condition of the product. The presentation of the product must not harm the image of the brand and its proprietor. If there is new packaging, it must clearly indicate the person who carried out the reconditioning and the product. Finally, the importer must notify the trade mark owner of the future sale and provide him with, on request, a specimen of the reconditioning.

These conditions allow the trade mark owner to maintain some control over the distribution of his products by parallel importers.

New opportunities for the parallel market are now offered by a decision recently rendered by the Court of Justice of the European Union (CJEU) (decision of the CJEU, May 17 2018 C-642/06).

In this case, the parallel importer added a new label on the pharmaceuticals to permit their importation. The trade mark owner opposed this commercialisation insofar as the importer failed to inform him about this reimport and the new packaging adopted.

The Court noted that in all cases until then the reconditioning had required the opening of the original packaging. Here, the packaging had not been modified, nor the original presentation affected.

The Court made the following points:

(i) the importer had limited himself to affixing an additional label on an unprinted part of the packaging, which had not been opened;

(ii) this label was small and included only the name of the parallel importer, its address and telephone number, a barcode and a pharmacological number.

As a result, affixing such a label did not contravene the trade mark holder's rights, and the parallel importer was not obliged to inform the trade mark holder of his action.

marie.jpg

Aurélia Marie

Cabinet Beau de Loménie

158, rue de l’Université

F - 75340 Paris Cedex 07 France

Tel: +33 1 44 18 89 00

Fax: +33 1 44 18 04 23

contact@bdl-ip.com

www.bdl-ip.com

more from across site and SHARED ros bottom lb

More from across our site

IPH, which owns several IP businesses in the APAC and Canada, reported a 16.5% increase in revenue and 13% jump in profit after tax
With Ireland’s government re-engaging with the idea of a UPC referendum, it provides a chance to improve the system further
US-based company says appointment of Jorge Ordonez shows its momentum as a private-equity-backed platform expanding in the IP services market
The firm hired an IP litigation team during the reporting period and has entered the Managing IP rankings for trademark work
Masaki Mikami of Marks IP explains how he helped prove acquired distinctiveness to secure protection for 'Pocky' in Japan
Daralyn Durie discusses the ‘amazing’ opportunity of working on an AI case, the value of celebrating women, and how to build the next wave of talent
New members of the Access Advance patent pool and Harvard University coming under fire were also among the top talking points
Team from Graham Watt & Co will join Beck Greener’s London office
The firm reported a small uptick in overall revenue and profit per equity partner, while its IP team secured notable life sciences victories
Paul Ainsworth, who secured a settlement for his client in a patent dispute, says the case shows why medical claims by dietary supplement companies can threaten IP rights
Gift this article